{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:12:23Z","timestamp":1791947543130,"version":"4.3.4"},"reference-count":260,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>For over 2 decades, the mevalonate pathway has been in focus as an interesting therapeutic target in Philadelphia chromosome\u2013negative myeloproliferative neoplasms (MPNs). Initially explored for its potential in cytoreductive and antithrombotic therapy, the role of statins in MPNs is now experiencing a compelling renaissance. This renewed interest is fueled by the recognition of MPNs as \u201ca human inflammation model,\u201d driven by chronic inflammation that fuels clonal expansion, premature atherosclerosis, fibrogenesis, and an increased risk of second cancers and comorbidities. Statins possess a wide spectrum of pleiotropic effects beyond lipid lowering, including anti-inflammatory, antiproliferative, proapoptotic, antiangiogenic, and antifibrotic properties. They dampen the activation of leukocytes, platelets, and endothelial cells. Recent epidemiological studies from Denmark demonstrate that statins protect against the development of MPNs in the general population. Furthermore, emerging clinical data suggest that statins enhance the efficacy of interferon alpha (IFN-\u03b1), the only known therapy capable of directly targeting the malignant stem cell and inducing minimal residual disease in a subset of patients. This review traces the 20-year journey of the statin-in-MPN concept, from its mechanistic rationale to the present, in which a confluence of evidence from comorbid disease prevention and oncoimmunology is supportive of their upfront use. I posit that we are at a watershed moment, at which statins should be integrated into the upfront treatment of MPNs and in combination therapy strategies, particularly with IFN-\u03b1, and potentially with ruxolitinib and metformin, to extinguish the chronic inflammatory drive and fundamentally alter the natural history of these neoplasms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026019625","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:47:24Z","timestamp":1772138844000},"page":"3587-3605","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Prime time for the use of statins in MPNs: from comorbidity drugs to disease-modifying partners"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3936-8032","authenticated-orcid":false,"given":"Hans C.","family":"Hasselbalch","sequence":"first","affiliation":[{"name":"Department of Hematology, Zealand University Hospital, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"issue":"2","key":"2026052610365531100_bib1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2174\/138945007779940133","article-title":"The mevalonate pathway as a therapeutic target in the Ph-negative chronic myeloproliferative disorders","volume":"8","author":"Hasselbalch","year":"2007","journal-title":"Curr Drug Targets"},{"issue":"10","key":"2026052610365531100_bib2","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.leukres.2005.12.018","article-title":"Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential?","volume":"30","author":"Hasselbalch","year":"2006","journal-title":"Leuk Res"},{"issue":"14","key":"2026052610365531100_bib3","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","article-title":"Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer","volume":"119","author":"Hasselbalch","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2026052610365531100_bib4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.leukres.2012.10.020","article-title":"Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?","volume":"37","author":"Hasselbalch","year":"2013","journal-title":"Leuk Res"},{"issue":"19","key":"2026052610365531100_bib5","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJMoa1201735","article-title":"Statin use and reduced cancer-related mortality","volume":"367","author":"Nielsen","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"2026052610365531100_bib6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/bjh.12103","article-title":"JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth","volume":"160","author":"Griner","year":"2013","journal-title":"Br J Haematol"},{"key":"2026052610365531100_bib7","first-page":"20","article-title":"A remarkable hematological and molecular response pattern in a patient with polycythemia vera during combination therapy with simvastatin and alendronate","volume":"6","author":"S\u00f8rensen","year":"2016","journal-title":"Leuk Res Rep"},{"key":"2026052610365531100_bib8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.thromres.2018.05.014","article-title":"Statin exposure and thrombosis risk in patients with myeloproliferative neoplasms","volume":"167","author":"Delluc","year":"2018","journal-title":"Thromb Res"},{"key":"2026052610365531100_bib9","doi-asserted-by":"crossref","first-page":"101088","DOI":"10.1016\/j.redox.2018.101088","article-title":"Statin treatment, oxidative stress and inflammation in a Danish population","volume":"21","author":"S\u00f8rensen","year":"2019","journal-title":"Redox Biol"},{"issue":"4","key":"2026052610365531100_bib10","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00277-020-03950-6","article-title":"The impact of statins on the intensity of phlebotomies in polycythemia vera","volume":"99","author":"Kre\u010dak","year":"2020","journal-title":"Ann Hematol"},{"issue":"14","key":"2026052610365531100_bib11","doi-asserted-by":"crossref","first-page":"e19596","DOI":"10.1097\/MD.0000000000019596","article-title":"Impact of statin use on cancer-specific mortality and recurrence: a meta-analysis of 60 observational studies","volume":"99","author":"Yang","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"2026052610365531100_bib12","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1172\/JCI124566","article-title":"Erythrocyte- derived microvesicles induce arterial spasms in JAK2V617F myeloproliferative neoplasm","volume":"130","author":"Poisson","year":"2020","journal-title":"J Clin Invest"},{"issue":"14","key":"2026052610365531100_bib13","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1182\/bloodadvances.2023009784","article-title":"Use of statins and risk of myeloproliferative neoplasms: a Danish nationwide case-control study","volume":"7","author":"Tuyet Kristensen","year":"2023","journal-title":"Blood Adv"},{"issue":"18","key":"2026052610365531100_bib14","doi-asserted-by":"crossref","first-page":"18889","DOI":"10.1002\/cam4.6528","article-title":"Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia","volume":"12","author":"Podoltsev","year":"2023","journal-title":"Cancer Med"},{"issue":"5","key":"2026052610365531100_bib15","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1007\/s00277-024-05693-0","article-title":"The impact of statin use on disease-related symptoms in patients with chronic myeloproliferative neoplasms","volume":"103","author":"Holik","year":"2024","journal-title":"Ann Hematol"},{"issue":"6","key":"2026052610365531100_bib16","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1161\/CIRCULATIONAHA.125.074544","article-title":"Association of statin treatment and dose with the clinical course of small abdominal aortic aneurysms in men: a 5-year prospective cohort study from 2 population-based screening trials","volume":"152","author":"Skovbo","year":"2025","journal-title":"Circulation"},{"issue":"23","key":"2026052610365531100_bib17","doi-asserted-by":"crossref","first-page":"6189","DOI":"10.1182\/bloodadvances.2025017016","article-title":"Statins enhance the efficacy of pegylated interferon-\u03b12 in Philadelphia-negative chronic myeloproliferative neoplasms","volume":"9","author":"Davidsen","year":"2025","journal-title":"Blood Adv"},{"issue":"8","key":"2026052610365531100_bib18","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/blood-2008-06-158386","article-title":"Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence","volume":"112","author":"Lataillade","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2026052610365531100_bib19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cytogfr.2013.01.004","article-title":"The role of cytokines in the initiation and progression of myelofibrosis","volume":"24","author":"Hasselbalch","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"issue":"2","key":"2026052610365531100_bib20","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/ejh.12437","article-title":"Perspectives on the increased risk of second cancer in patients with essential thrombocythemia, polycythemia vera and myelofibrosis","volume":"94","author":"Hasselbalch","year":"2015","journal-title":"Eur J Haematol"},{"issue":"2","key":"2026052610365531100_bib21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1586\/17474086.2013.876356","article-title":"Perspectives on the impact of JAK-inhibitor therapy upon inflammation- mediated comorbidities in myelofibrosis and related neoplasms","volume":"7","author":"Hasselbalch","year":"2014","journal-title":"Expert Rev Hematol"},{"issue":"10","key":"2026052610365531100_bib22","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.leukres.2014.07.006","article-title":"The platelet-cancer loop in myeloproliferative cancer. Is thrombocythemia an enhancer of cancer invasiveness and metastasis in essential thrombocythemia, polycythemia vera and myelofibrosis?","volume":"38","author":"Hasselbalch","year":"2014","journal-title":"Leuk Res"},{"key":"2026052610365531100_bib23","doi-asserted-by":"crossref","first-page":"102476","DOI":"10.1155\/2015\/102476","article-title":"MPNs as inflammatory diseases: the evidence, consequences, and perspectives","volume":"2015","author":"Hasselbalch","year":"2015","journal-title":"Mediators Inflamm"},{"key":"2026052610365531100_bib24","doi-asserted-by":"crossref","first-page":"648090","DOI":"10.1155\/2015\/648090","article-title":"The role of reactive oxygen species in myelofibrosis and related neoplasms","volume":"2015","author":"Bj\u00f8rn","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"5","key":"2026052610365531100_bib25","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/17474086.2017.1284583","article-title":"Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib","volume":"10","author":"Bj\u00f8rn","year":"2017","journal-title":"Expert Rev Hematol"},{"issue":"16","key":"2026052610365531100_bib26","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1182\/blood.2020008109","article-title":"The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms","volume":"137","author":"Hasselbalch","year":"2021","journal-title":"Blood"},{"issue":"17","key":"2026052610365531100_bib27","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.3390\/cancers15174323","article-title":"Revisiting circulating extracellular matrix fragments as disease markers in myelofibrosis and related neoplasms","volume":"15","author":"Hasselbalch","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2026052610365531100_bib28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-018-0700-2","article-title":"Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?","volume":"41","author":"Hasselbalch","year":"2019","journal-title":"Semin Immunopathol"},{"key":"2026052610365531100_bib29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.cytogfr.2021.03.006","article-title":"COVID-19 as a mediator of interferon deficiency and hyperinflammation: rationale for the use of JAK1\/2 inhibitors in combination with interferon","volume":"60","author":"Hasselbalch","year":"2021","journal-title":"Cytokine Growth Factor Rev"},{"issue":"12","key":"2026052610365531100_bib30","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1097\/HS9.0000000000000645","article-title":"New perspectives of interferon-alpha2 and inflammation in treating Philadelphia-negative chronic myeloproliferative neoplasms","volume":"5","author":"Hasselbalch","year":"2021","journal-title":"Hemasphere"},{"issue":"10","key":"2026052610365531100_bib31","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"issue":"20","key":"2026052610365531100_bib32","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1200\/JCO.2014.57.6652","article-title":"Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study","volume":"33","author":"Hultcrantz","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026052610365531100_bib33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.leukres.2015.11.017","article-title":"Antecedent cardiovascular disease and autoimmunity in Philadelphia-negative chronic myeloproliferative neoplasms","volume":"41","author":"S\u00f8rensen","year":"2016","journal-title":"Leuk Res"},{"issue":"1","key":"2026052610365531100_bib34","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1002\/ajh.24583","article-title":"The effect of arterial hypertension on thrombosis in low-risk polycythemia vera","volume":"92","author":"Barbui","year":"2017","journal-title":"Am J Hematol"},{"key":"2026052610365531100_bib35","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2147\/CLEP.S216787","article-title":"Vascular diseases in patients with chronic myeloproliferative neoplasms - impact of comorbidity","volume":"11","author":"Frederiksen","year":"2019","journal-title":"Clin Epidemiol"},{"key":"2026052610365531100_bib36","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ijcard.2022.06.029","article-title":"Coronary artery- and aortic valve calcifications in patients with Philadelphia-negative myeloproliferative neoplasms","volume":"364","author":"Solli","year":"2022","journal-title":"Int J Cardiol"},{"issue":"3","key":"2026052610365531100_bib37","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/ejh.14019","article-title":"High JAK2V617F variant allele frequency is associated with coronary artery but not aortic valve calcifications in patients with Philadelphia-negative myeloproliferative neoplasms","volume":"111","author":"Solli","year":"2023","journal-title":"Eur J Haematol"},{"issue":"3","key":"2026052610365531100_bib38","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/bloodadvances.2023012190","article-title":"CHIP-JAK2V617F, chronic inflammation, abnormal megakaryocyte morphology, organ failure, and multimorbidities","volume":"8","author":"Hasselbalch","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"2026052610365531100_bib39","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41408-024-00994-z","article-title":"Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study","volume":"14","author":"Larsen","year":"2024","journal-title":"Blood Cancer J"},{"issue":"20","key":"2026052610365531100_bib40","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.3390\/jcm13206084","article-title":"Thrombotic, cardiovascular, and microvascular complications of myeloproliferative neoplasms and clonal hematopoiesis (CHIP): a narrative review","volume":"13","author":"Schafer","year":"2024","journal-title":"J Clin Med"},{"issue":"10","key":"2026052610365531100_bib41","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s11864-024-01255-8","article-title":"Myeloproliferative neoplasms and cardiovascular disease: a review","volume":"25","author":"Leiva","year":"2024","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"2026052610365531100_bib42","doi-asserted-by":"crossref","first-page":"oeae101","DOI":"10.1093\/ehjopen\/oeae101","article-title":"Trends and disparities in cardiovascular disease-related mortality among adults with myeloproliferative neoplasms in USA","volume":"5","author":"Agarwal","year":"2025","journal-title":"Eur Heart J Open"},{"key":"2026052610365531100_bib43","doi-asserted-by":"crossref","first-page":"119046","DOI":"10.1016\/j.atherosclerosis.2024.119046","article-title":"Readmission outcomes after acute coronary syndrome among patients with myeloproliferative neoplasms","volume":"401","author":"Leiva","year":"2025","journal-title":"Atherosclerosis"},{"issue":"1","key":"2026052610365531100_bib44","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1158\/1055-9965.EPI-25-0969","article-title":"Risk of cardiovascular and cerebrovascular diseases in patients with myeloid neoplasms: results from 1.8 million inhabitants of North-West Italy","volume":"35","author":"Catalano","year":"2026","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"2026052610365531100_bib45","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jtha.2025.09.015","article-title":"TET2 mutations in myeloproliferative neoplasms: potential mediation of atrial fibrillation by IL-1\u03b2 and impact on stroke risk in clinical cohorts","volume":"24","author":"Teng","year":"2026","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2026052610365531100_bib46","doi-asserted-by":"crossref","first-page":"100051","DOI":"10.1016\/j.bvth.2025.100051","article-title":"Cardiovascular risk factors in myeloproliferative neoplasms: associations with survival and thrombotic outcomes","volume":"2","author":"How","year":"2025","journal-title":"Blood Vessel Thromb Hemost"},{"issue":"4","key":"2026052610365531100_bib47","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1007\/s00277-025-06334-w","article-title":"Transformed to myelofibrosis is a risk factor for pulmonary hypertension in Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"104","author":"Suolitiken","year":"2025","journal-title":"Ann Hematol"},{"issue":"5","key":"2026052610365531100_bib48","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jaccao.2025.05.010","article-title":"Beyond thrombosis: pulmonary hypertension and heart failure in patients with myeloproliferative neoplasms: JACC: CardioOncology State-of-the-Art Review","volume":"7","author":"Leiva","year":"2025","journal-title":"JACC CardioOncol"},{"issue":"6","key":"2026052610365531100_bib49","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1182\/bloodadvances.2024013970","article-title":"High pulmonary hypertension risk by echocardiogram shortens survival in polycythemia vera","volume":"9","author":"Gazda","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"2026052610365531100_bib50","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/joim.70037","article-title":"The JAK2V617F and CALR mutations and risk of cancer, cardiovascular diseases, and all-cause mortality","volume":"299","author":"Larsen","year":"2026","journal-title":"J Intern Med"},{"key":"2026052610365531100_bib51","doi-asserted-by":"publisher","DOI":"10.1055\/a-2767-0451","article-title":"Atrial Fibrillation in Philadelphia-Chromosome Negative MPNs: Thromboinflammatory Crosstalk with Focus on the NLRP3 Inflammasome","author":"Demska","year":"23  2025","journal-title":"Trombosis and Haemostasis"},{"issue":"6257","key":"2026052610365531100_bib52","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/343425a0","article-title":"Regulation of the mevalonate pathway","volume":"343","author":"Goldstein","year":"1990","journal-title":"Nature"},{"issue":"5307","key":"2026052610365531100_bib53","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1126\/science.275.5307.1750","article-title":"Protein prenylation, et cetera: signal transduction in two dimensions","volume":"275","author":"Gelb","year":"1997","journal-title":"Science"},{"key":"2026052610365531100_bib54","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1182\/blood.V94.9.2971","article-title":"Ras proteins: recent advances and new functions","volume":"94","author":"Rebello","year":"1999","journal-title":"Blood"},{"issue":"1","key":"2026052610365531100_bib55","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0092-8674(00)80601-7","article-title":"New insights into the interaction of Ras with the cell membrane","volume":"98","author":"Magee","year":"1999","journal-title":"Cell"},{"issue":"5","key":"2026052610365531100_bib56","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1182\/blood.V96.5.1655","article-title":"Targeting the Ras signalling pathway: a rational, mechanism-based treatment of hematologic malignancies?","volume":"96","author":"Reuter","year":"2000","journal-title":"Blood"},{"issue":"4","key":"2026052610365531100_bib57","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1084\/jem.20040061","article-title":"Statins inhibit HIV-1 infection by down-regulating Rho activity","volume":"200","author":"del Real","year":"2004","journal-title":"J Exp Med"},{"issue":"1","key":"2026052610365531100_bib58","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1756-9966-30-74","article-title":"Statin-induced apoptosis via the suppression of ERK1\/2 and Akt activation by inhibition of the geranylgeranyl- pyrophosphate biosynthesis in glioblastoma","volume":"30","author":"Yanae","year":"2011","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"2026052610365531100_bib59","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/nrc.2016.76","article-title":"The interplay between cell signalling and the mevalonate pathway in cancer","volume":"16","author":"Mullen","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2026052610365531100_bib60","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41577-018-0094-3","article-title":"Statins: a viable candidate for host-directed therapy against infectious diseases","volume":"19","author":"Parihar","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"2026052610365531100_bib61","doi-asserted-by":"crossref","first-page":"626971","DOI":"10.3389\/fonc.2021.626971","article-title":"The mevalonate pathway, a metabolic target in cancer therapy","volume":"11","author":"Guerra","year":"2021","journal-title":"Front Oncol"},{"issue":"18","key":"2026052610365531100_bib62","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1161\/CIRCULATIONAHA.121.054183","article-title":"Statins do more than lower cholesterol-depending on what you eat?","volume":"143","author":"Eschenhagen","year":"2021","journal-title":"Circulation"},{"issue":"18","key":"2026052610365531100_bib63","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1161\/CIRCULATIONAHA.120.046542","article-title":"Dietary geranylgeranyl pyrophosphate counteracts the benefits of statin therapy in experimental pulmonary hypertension","volume":"143","author":"Zhu","year":"2021","journal-title":"Circulation"},{"issue":"5","key":"2026052610365531100_bib64","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.21037\/jtd-2025-66","article-title":"Statins as potential adjuvant therapy in lung cancer: a narrative review","volume":"17","author":"Tian","year":"2025","journal-title":"J Thorac Dis"},{"key":"2026052610365531100_bib65","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/01.CIR.100.3.230","article-title":"Long- term effects of pravastatin on plasma concentrations of C-reactive protein","volume":"100","author":"Ridker","year":"1999","journal-title":"Circulation"},{"issue":"9","key":"2026052610365531100_bib66","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1161\/01.CIR.103.9.1191","article-title":"Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia","volume":"103","author":"Ridker","year":"2001","journal-title":"Circulation"},{"issue":"20","key":"2026052610365531100_bib67","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1161\/01.CIR.97.20.2007","article-title":"C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction","volume":"97","author":"Ridker","year":"1998","journal-title":"Circulation"},{"issue":"2","key":"2026052610365531100_bib68","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/01.CIR.99.2.237","article-title":"C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Chort Study, 1984 to 1992","volume":"99","author":"Koenig","year":"1999","journal-title":"Circulation"},{"issue":"9","key":"2026052610365531100_bib69","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0002-9149(99)00491-9","article-title":"Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men","volume":"84","author":"Rohde","year":"1999","journal-title":"Am J Cardiol"},{"issue":"12","key":"2026052610365531100_bib70","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women","volume":"342","author":"Ridker","year":"2000","journal-title":"N Engl J Med"},{"issue":"9157","key":"2026052610365531100_bib71","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(98)05917-0","article-title":"Inhibition of proinflammatory cytokine production by pravastatin","volume":"353","author":"Rosenson","year":"1999","journal-title":"Lancet"},{"issue":"6","key":"2026052610365531100_bib72","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00001721-200408000-00004","article-title":"Increased soluble CD40L levels are reduced by long term simvastatin in peritoneally dialyzed patients","volume":"15","author":"Malyszko","year":"2004","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"Pt 2","key":"2026052610365531100_bib73","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1042\/bj3480241","article-title":"Rho GTPases and their effector proteins","volume":"348","author":"Bishop","year":"2000","journal-title":"Biochem J"},{"issue":"17","key":"2026052610365531100_bib116","doi-asserted-by":"crossref","first-page":"8429","DOI":"10.3390\/ijms26178429","article-title":"Molecular and immunomodulatory mechanisms of statins in inflammation and cancer therapeutics with emphasis on the NF- \u03baB, NLRP3 inflammasome, and cytokine regulatory axes","volume":"26","author":"Khan","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2026052610365531100_bib74","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0021-9150(99)00193-8","article-title":"Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells","volume":"147","author":"Ortego","year":"1999","journal-title":"Atherosclerosis"},{"issue":"5","key":"2026052610365531100_bib75","first-page":"696","article-title":"Simvastatin inhibits cytokine production and nuclear factor-kB activation in interleukin 1beta-stimulated synoviocytes from rheumatoid arthritis patients","volume":"25","author":"Lazzerini","year":"2007","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"2026052610365531100_bib76","doi-asserted-by":"crossref","first-page":"397","DOI":"10.5414\/CPP41397","article-title":"Statins differ in their ability to block NF-kappaB activation in human blood monocytes","volume":"41","author":"Hilgendorff","year":"2003","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"2026052610365531100_bib77","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.fjc.0000175455.46245.c8","article-title":"Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates","volume":"46","author":"Okopie\u0144","year":"2005","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"2026052610365531100_bib78","first-page":"463","article-title":"Simvastatin inhibits production of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-alpha in fibroblast-like synoviocytes from patients with rheumatoid arthritis","volume":"33","author":"Yokota","year":"2006","journal-title":"J Rheumatol"},{"issue":"6","key":"2026052610365531100_bib79","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/j.1476-5381.2009.00612.x","article-title":"Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase\/signal transducers and activators of transcription pathways in human vascular endothelial cells","volume":"159","author":"Jougasaki","year":"2010","journal-title":"Br J Pharmacol"},{"issue":"9","key":"2026052610365531100_bib80","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1253\/circj.CJ-11-1123","article-title":"Effects of statin therapy on the production of monocyte pro-inflammatory cytokines, cardiac function, and long-term prognosis in chronic heart failure patients with dyslipidemia","volume":"76","author":"Nakagomi","year":"2012","journal-title":"Circ J"},{"issue":"1","key":"2026052610365531100_bib81","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3109\/14017431.2012.734635","article-title":"Effects of simvastatin and ezetimibe on interleukin-6 and high-sensitivity C-reactive protein","volume":"47","author":"Berthold","year":"2013","journal-title":"Scand Cardiovasc J"},{"issue":"5","key":"2026052610365531100_bib82","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/annrheumdis-2012-201887","article-title":"Simvastatin inhibits the pro-inflammatory and pro- thrombotic effects of IL-17 and TNF-\u03b1 on endothelial cells","volume":"72","author":"Hot","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2026052610365531100_bib83","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nri910","article-title":"NF-kappaB regulation in the immune system","volume":"2","author":"Verma","year":"2002","journal-title":"Nat Rev Immunol"},{"issue":"23","key":"2026052610365531100_bib84","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1182\/blood.2024024451","article-title":"Relating NF-\u03baB regulation to MPN pathogenesis","volume":"143","author":"Sullivan","year":"2024","journal-title":"Blood"},{"issue":"23","key":"2026052610365531100_bib85","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1182\/blood.2023022804","article-title":"In vivo ablation of NF-\u03baB cascade effectors alleviates disease burden in myeloproliferative neoplasms","volume":"143","author":"Laranjeira","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2026052610365531100_bib86","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.4049\/jimmunol.153.6.2819","article-title":"Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines: potential role for interleukin-1 and TGF-beta","volume":"153","author":"Rameshwar","year":"1994","journal-title":"J Immunol"},{"issue":"2","key":"2026052610365531100_bib87","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/(SICI)1096-8652(199810)59:2<133::AID-AJH6>3.0.CO;2-Z","article-title":"Systemic transforming growth factor-beta in patients with bone marrow fibrosis: pathophysiological implications","volume":"59","author":"Rameshwar","year":"1998","journal-title":"Am J Hematol"},{"issue":"8","key":"2026052610365531100_bib88","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1158\/0008-5472.CAN-04-2339","article-title":"Role for the nuclear factor kappaB pathway in transforming growth factor-beta1 production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression","volume":"65","author":"Komura","year":"2005","journal-title":"Cancer Res"},{"issue":"21 suppl 1","key":"2026052610365531100_bib89","first-page":"II15","article-title":"Statins as immunomodulatory agents","volume":"109","author":"Mach","year":"2004","journal-title":"Circulation"},{"key":"2026052610365531100_bib90","doi-asserted-by":"crossref","first-page":"1196817","DOI":"10.3389\/fonc.2023.1196817","article-title":"Mutations, inflammation and phenotype of myeloproliferative neoplasms","volume":"13","author":"Hermouet","year":"2023","journal-title":"Front Oncol"},{"issue":"3","key":"2026052610365531100_bib91","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.1097\/HS9.0000000000000371","article-title":"Longitudinal cytokine profiling identifies GRO-\u03b1 and EGF as potential biomarkers of disease progression in essential thrombocythemia","volume":"4","author":"\u00d8bro","year":"2020","journal-title":"Hemasphere"},{"issue":"3","key":"2026052610365531100_bib92","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.1097\/HS9.0000000000000407","article-title":"Cytokine profiling as a novel complementary tool to predict prognosis in MPNs?","volume":"4","author":"Hasselbalch","year":"2020","journal-title":"Hemasphere"},{"issue":"7","key":"2026052610365531100_bib93","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3324\/haematol.2009.020412","article-title":"Autoimmunity and the risk of myeloproliferative neoplasms","volume":"95","author":"Kristinsson","year":"2010","journal-title":"Haematologica"},{"issue":"4","key":"2026052610365531100_bib94","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11899-014-0227-0","article-title":"An immune dysregulation in MPN","volume":"9","author":"Barosi","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"issue":"7","key":"2026052610365531100_bib95","doi-asserted-by":"crossref","first-page":"614","DOI":"10.2174\/1574888X15666200225092749","article-title":"Overview of therapeutic effects of statins on inflammatory diseases through regulating adhesive molecules","volume":"15","author":"Meng","year":"2020","journal-title":"Curr Stem Cell Res Ther"},{"issue":"1","key":"2026052610365531100_bib96","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12026-025-09653-2","article-title":"Statins and adhesion molecules: a review of a novel pleiotropic property of statins","volume":"73","author":"Sadeghi","year":"2025","journal-title":"Immunol Res"},{"issue":"5","key":"2026052610365531100_bib97","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1160\/TH12-05-0337","article-title":"Translating the effects of statins: from redox regulation to suppression of vascular wall inflammation","volume":"108","author":"Antonopoulos","year":"2012","journal-title":"Thromb Haemost"},{"key":"2026052610365531100_bib98","doi-asserted-by":"publisher","DOI":"10.2174\/1381612823666170926130338","article-title":"Statins and oxidative stress in the cardiovascular system","author":"Margaritis","year":"26  2017","journal-title":"Curr Pharm Des"},{"issue":"3","key":"2026052610365531100_bib99","doi-asserted-by":"crossref","first-page":"e004746","DOI":"10.1161\/JAHA.116.004746","article-title":"Rac1 pharmacological inhibition rescues human endothelial dysfunction","volume":"6","author":"Carrizzo","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2026052610365531100_bib100","doi-asserted-by":"crossref","first-page":"1515864","DOI":"10.3389\/fphar.2025.1515864","article-title":"Inflammation pathways as therapeutic targets in angiotensin II induced atrial fibrillation","volume":"16","author":"Hou","year":"2025","journal-title":"Front Pharmacol"},{"issue":"5","key":"2026052610365531100_bib134","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1161\/CIRCULATIONAHA.125.074002","article-title":"Aortic aneurysm risk and the somatic JAK2V617F mutation: insights from a multicenter, population- based cardiovascular screening study","volume":"152","author":"Obel","year":"2025","journal-title":"Circulation"},{"issue":"1","key":"2026052610365531100_bib135","doi-asserted-by":"crossref","first-page":"E17","DOI":"10.1002\/ajh.23874","article-title":"Occurrence of the JAK2 V617F mutation in patients with peripheral arterial disease","volume":"90","author":"Muendlein","year":"2015","journal-title":"Am J Hematol"},{"key":"2026052610365531100_bib136","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.thromres.2023.04.021","article-title":"Atrial fibrillation and peripheral arterial disease define MPN patients with very high risk of thrombosis","volume":"226","author":"Herbreteau","year":"2023","journal-title":"Thromb Res"},{"issue":"8","key":"2026052610365531100_bib137","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s11239-025-03088-0","article-title":"Outcomes of patients with myeloproliferative neoplasms and critical limb ischemia: insights from the National readmissions database","volume":"58","author":"Leiva","year":"2025","journal-title":"J Thromb Thrombolysis"},{"key":"2026052610365531100_bib227","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-026-02882-w","article-title":"A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alpha","author":"Silver","year":"2026  8","journal-title":"Leukemia"},{"issue":"5","key":"2026052610365531100_bib228","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41375-018-0019-y","article-title":"Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"9","key":"2026052610365531100_bib215","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3390\/medicina61091563","article-title":"The impact of statin use on sepsis mortality: a systematic review and meta-analysis","volume":"61","author":"Philippou","year":"2025","journal-title":"Medicina (Kaunas)"},{"issue":"5","key":"2026052610365531100_bib216","doi-asserted-by":"crossref","first-page":"e70046","DOI":"10.1111\/fcp.70046","article-title":"Statins as antifungal agents: a review on drug repurposing and nanotechnology-driven delivery strategies","volume":"39","author":"E Silva","year":"2025","journal-title":"Fundam Clin Pharmacol"},{"issue":"21","key":"2026052610365531100_bib217","doi-asserted-by":"crossref","first-page":"13006","DOI":"10.3390\/ijms232113006","article-title":"Innovations in evaluating statin benefit and efficacy in Staphylococcus aureus intracellular infection management","volume":"23","author":"Nesson","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2026052610365531100_bib218","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1021\/acsinfecdis.5c00309","article-title":"Simvastatin administration prohibits Staphylococcus aureus anti-ROS adaptation in vivo and alleviates bone infections","volume":"11","author":"Chen","year":"2025","journal-title":"ACS Infect Dis"},{"issue":"12","key":"2026052610365531100_bib219","doi-asserted-by":"crossref","first-page":"ofae697","DOI":"10.1093\/ofid\/ofae697","article-title":"Baseline statin use appears to protect against severe COVID-19","volume":"11","author":"Meyerowitz","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"2026052610365531100_bib220","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s11239-023-02910-x","article-title":"HMG-CoA reductase inhibitors and the attenuation of risk for disseminated intravascular coagulation in patients with sepsis","volume":"57","author":"Alana","year":"2024","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"2026052610365531100_bib221","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/08923973.2024.2436089","article-title":"Effect of atorvastatin on lipopolysaccharide-induced lung inflammation and hypoxia in mice; modulation of HIF-1\u03b1, CINC and MIP-2","volume":"47","author":"Salama","year":"2025","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"1","key":"2026052610365531100_bib101","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/ejh.14297","article-title":"Myeloproliferative neoplasms and dementia risk: a population-based cohort study","volume":"114","author":"Sun","year":"2025","journal-title":"Eur J Haematol"},{"issue":"1","key":"2026052610365531100_bib105","doi-asserted-by":"crossref","first-page":"e70039","DOI":"10.1002\/trc2.70039","article-title":"Statin use and dementia risk: a systematic review and updated meta- analysis","volume":"11","author":"Westphal Filho","year":"2025","journal-title":"Alzheimers Dement (N Y)"},{"issue":"9","key":"2026052610365531100_bib117","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1177\/15353702231181188","article-title":"Repurposing medications for treatment of age-related macular degeneration: insights from novel approaches to data mining","volume":"248","author":"Moir","year":"2023","journal-title":"Exp Biol Med (Maywood)"},{"key":"2026052610365531100_bib118","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ajo.2025.08.024","article-title":"Potency matters: the role of statin intensity in modulating risk for age-related macular degeneration","volume":"280","author":"Hussain","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"2026052610365531100_bib119","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1002\/bcp.70128","article-title":"Impact of long-term statin therapy on age-related macular degeneration: a nationwide population-based study","volume":"91","author":"Chen","year":"2025","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"2026052610365531100_bib120","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1007\/s10753-024-02179-z","article-title":"Atorvastatin alleviates age- related macular degeneration via AIM2-regulated pyroptosis","volume":"48","author":"Lu","year":"2025","journal-title":"Inflammation"},{"issue":"4","key":"2026052610365531100_bib138","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.leukres.2014.01.014","article-title":"Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms","volume":"38","author":"Christensen","year":"2014","journal-title":"Leuk Res"},{"issue":"4","key":"2026052610365531100_bib139","doi-asserted-by":"crossref","first-page":"790","DOI":"10.3904\/kjim.2016.263","article-title":"Chronic kidney disease in the BCR-ABL1-negative myeloproliferative neoplasm: a single-center retrospective study","volume":"33","author":"Baek","year":"2018","journal-title":"Korean J Intern Med"},{"issue":"3","key":"2026052610365531100_bib140","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s12185-020-02898-7","article-title":"Chronic kidney disease could be a risk factor for thrombosis in essential thrombocythemia and polycythemia vera","volume":"112","author":"Kre\u010dak","year":"2020","journal-title":"Int J Hematol"},{"issue":"12","key":"2026052610365531100_bib141","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1007\/s00277-020-04239-4","article-title":"Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis","volume":"99","author":"Lucijanic","year":"2020","journal-title":"Ann Hematol"},{"issue":"16","key":"2026052610365531100_bib142","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.3390\/cancers13164086","article-title":"Kidney dysfunction is associated with thrombosis and disease severity in myeloproliferative neoplasms: implications from the German Study Group for MPN Bioregistry","volume":"13","author":"Gecht","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2026052610365531100_bib143","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/ejh.13845","article-title":"Clonal haematopoiesis of indeterminate potential and impaired kidney function-a Danish general population study with 11 years follow-up","volume":"109","author":"Larsen","year":"2022","journal-title":"Eur J Haematol"},{"issue":"3","key":"2026052610365531100_bib144","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41581-023-00778-x","article-title":"Clonal haematopoiesis, ageing and kidney disease","volume":"20","author":"Vlasschaert","year":"2024","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"2026052610365531100_bib146","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13098-024-01514-6","article-title":"Simvastatin reduces chronic kidney disease and renal failure risk in type 2 diabetes patients: post hoc ACCORD trial analysis","volume":"16","author":"Pu","year":"2024","journal-title":"Diabetol Metab Syndr"},{"issue":"14","key":"2026052610365531100_bib147","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.7150\/ijms.114382","article-title":"Role of metabolic abnormalities during the progression of chronic kidney disease and preventive strategies","volume":"22","author":"Zha","year":"2025","journal-title":"Int J Med Sci"},{"issue":"1","key":"2026052610365531100_bib148","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2478\/acph-2025-0002","article-title":"The impact of blood lipids and statins on renal function and mortality in patients with diabetic nephropathy: a meta-analysis","volume":"75","author":"Tian","year":"2025","journal-title":"Acta Pharm"},{"issue":"5","key":"2026052610365531100_bib160","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/bjh.12581","article-title":"Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population- based cohort study","volume":"163","author":"Farmer","year":"2013","journal-title":"Br J Haematol"},{"issue":"21","key":"2026052610365531100_bib161","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1182\/blood.2021011480","article-title":"Myeloproliferative disorders and their effects on bone homeostasis: the role of megakaryocytes","volume":"139","author":"Karagianni","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2026052610365531100_bib162","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1007\/s40618-023-02095-3","article-title":"Study of the link between hemotopoietic and skeletal systems in patients attending a referral center for osteoporosis","volume":"46","author":"Pepe","year":"2023","journal-title":"J Endocrinol Invest"},{"issue":"28","key":"2026052610365531100_bib163","doi-asserted-by":"crossref","first-page":"e20906","DOI":"10.1097\/MD.0000000000020906","article-title":"Association of bone mineral density with Peripheral blood cell counts and hemoglobin in Chinese postmenopausal women: a retrospective study","volume":"99","author":"Li","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"2026052610365531100_bib164","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00198-020-05766-6","article-title":"High platelet count is associated with low bone mineral density: the MrOS Sweden cohort","volume":"32","author":"Kristjansdottir","year":"2021","journal-title":"Osteoporos Int"},{"issue":"9","key":"2026052610365531100_bib165","doi-asserted-by":"crossref","first-page":"e72033","DOI":"10.1371\/journal.pone.0072033","article-title":"Stimulation of osteoclast formation by RANKL requires interferon regulatory factor-4 and is inhibited by simvastatin in a mouse model of bone loss","volume":"8","author":"Nakashima","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"2026052610365531100_bib166","doi-asserted-by":"crossref","first-page":"e3603","DOI":"10.1002\/dmrr.3603","article-title":"Statin use in patients with type 2 diabetes has lower risk of hip fractures: a Taiwan national population- based study","volume":"39","author":"Lee","year":"2023","journal-title":"Diabetes Metab Res Rev"},{"issue":"25","key":"2026052610365531100_bib179","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1182\/blood-2011-04-348755","article-title":"Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study","volume":"118","author":"Frederiksen","year":"2011","journal-title":"Blood"},{"issue":"7","key":"2026052610365531100_bib180","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(15)00092-7","article-title":"Survival of patients with chronic myeloproliferative neoplasms and new primary cancers: a population-based cohort study","volume":"2","author":"Frederiksen","year":"2015","journal-title":"Lancet Haematol"},{"issue":"1","key":"2026052610365531100_bib102","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s12974-020-01877-3","article-title":"Myeloproliferative blood cancers as a human neuroinflammation model for development of Alzheimer's disease: evidences and perspectives","volume":"17","author":"Hasselbalch","year":"2020","journal-title":"J Neuroinflammation"},{"issue":"23","key":"2026052610365531100_bib103","doi-asserted-by":"crossref","first-page":"13669","DOI":"10.18632\/aging.205217","article-title":"Atorvastatin mitigates memory deficits and brain monocyte infiltration in chronic hypercholesterolemia","volume":"15","author":"Gong","year":"2023","journal-title":"Aging (Albany NY)"},{"key":"2026052610365531100_bib104","doi-asserted-by":"crossref","first-page":"1526959","DOI":"10.3389\/fneur.2025.1526959","article-title":"Correlation of atorvastatin with subjective memory deficits: a study from the NHANES and FAERS databases","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Neurol"},{"issue":"2","key":"2026052610365531100_bib106","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40268-024-00474-6","article-title":"Exploring the relationship between atorvastatin and memory loss: a comprehensive analysis integrating real-world pharmacovigilance and mendelian randomization","volume":"24","author":"Chen","year":"2024","journal-title":"Drugs R D"},{"issue":"8","key":"2026052610365531100_bib107","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jamaophthalmol.2017.2011","article-title":"Age- related macular degeneration in patients with chronic myeloproliferative neoplasms","volume":"135","author":"Bak","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"2026052610365531100_bib108","doi-asserted-by":"crossref","first-page":"100526","DOI":"10.1016\/j.eclinm.2020.100526","article-title":"Patients with myeloproliferative neoplasms and high levels of systemic inflammation develop age-related macular degeneration","volume":"26","author":"Liisborg","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2026052610365531100_bib109","doi-asserted-by":"crossref","first-page":"101248","DOI":"10.1016\/j.eclinm.2021.101248","article-title":"Patients with MPNs and retinal drusen show signs of complement system dysregulation and a high degree of chronic low- grade inflammation","volume":"43","author":"Liisborg","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"suppl 271","key":"2026052610365531100_bib110","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/aos.15247","article-title":"Age-related macular degeneration and myeloproliferative neoplasms - a common pathway","volume":"100","author":"Liisborg","year":"2022","journal-title":"Acta Ophthalmol"},{"issue":"24","key":"2026052610365531100_bib111","doi-asserted-by":"crossref","first-page":"25763","DOI":"10.18632\/aging.203803","article-title":"Retinal drusen in patients with chronic myeloproliferative blood cancers are associated with an increased proportion of senescent T cells and signs of an aging immune system","volume":"13","author":"Liisborg","year":"2021","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"2026052610365531100_bib112","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1038\/s41598-023-31078-w","article-title":"Serum levels of IL- 4, IL-13 and IL-33 in patients with age-related macular degeneration and myeloproliferative neoplasms","volume":"13","author":"Gotfredsen","year":"2023","journal-title":"Sci Rep"},{"issue":"2","key":"2026052610365531100_bib113","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1167\/iovs.66.2.41","article-title":"High levels of C5a are associated with reduced macular sensitivity in patients with myeloproliferative neoplasms","volume":"66","author":"Gotfredsen","year":"2025","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026052610365531100_bib114","doi-asserted-by":"crossref","first-page":"1336357","DOI":"10.3389\/fendo.2024.1336357","article-title":"Distinct effects of rosuvastatin and rosuvastatin\/ezetimibe on senescence markers of CD8+ T cells in patients with type 2 diabetes mellitus: a randomized controlled trial","volume":"15","author":"Ju","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2026052610365531100_bib115","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10522-018-9771-7","article-title":"Reversing the immune ageing clock: lifestyle modifications and pharmacological interventions","volume":"19","author":"Duggal","year":"2018","journal-title":"Biogerontology"},{"issue":"5","key":"2026052610365531100_bib121","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/leu.2016.12","article-title":"Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both","volume":"30","author":"Koschmieder","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"2026052610365531100_bib122","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood.2019001113","article-title":"Prevalence and phenotypes of JAK2V617F and calreticulin mutations in a Danish general population","volume":"134","author":"Cordua","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2026052610365531100_bib123","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1038\/s41375-021-01159-8","article-title":"Early detection of myeloproliferative neoplasms in a Danish general population study","volume":"35","author":"Cordua","year":"2021","journal-title":"Leukemia"},{"issue":"6","key":"2026052610365531100_bib124","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s40291-024-00737-7","article-title":"Clonal hematopoiesis from a diagnostic perspective: 10 years of CHIP","volume":"28","author":"Kj\u00e6r","year":"2024","journal-title":"Mol Diagn Ther"},{"issue":"2","key":"2026052610365531100_bib125","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"2026052610365531100_bib126","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jacc.2017.12.037","article-title":"Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL- 1\u03b2\/NLRP3 inflammasome","volume":"71","author":"Sano","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"2026052610365531100_bib127","first-page":"1606","article-title":"Clonal hematopoiesis and nonhematologic disorders","volume":"136","author":"Jaiswal","year":"2020","journal-title":"Blood"},{"key":"2026052610365531100_bib128","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.yjmcc.2021.07.004","article-title":"Clonal hematopoiesis of indeterminate potential (CHIP): linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease","volume":"161","author":"Marnell","year":"2021","journal-title":"J Mol Cell Cardiol"},{"issue":"4","key":"2026052610365531100_bib129","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ajh.26465","article-title":"Association of clonal hematopoiesis mutations with clinical outcomes: a systematic review and meta- analysis","volume":"97","author":"Nowakowska","year":"2022","journal-title":"Am J Hematol"},{"key":"2026052610365531100_bib130","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-med-042921-112347","article-title":"Clonal hematopoiesis and its impact on human health","volume":"74","author":"Ahmad","year":"2023","journal-title":"Annu Rev Med"},{"issue":"19","key":"2026052610365531100_bib131","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1182\/bloodadvances.2023010588","article-title":"JAK2V617F mutation is highly prevalent in patients with ischemic stroke: a case-control study","volume":"7","author":"Kristiansen","year":"2023","journal-title":"Blood Adv"},{"key":"2026052610365531100_bib132","doi-asserted-by":"crossref","first-page":"109236","DOI":"10.1016\/j.thromres.2024.109236","article-title":"Thromboinflammation in ischemic cerebrovascular patients with the JAK2V617F mutation","volume":"245","author":"Kristiansen","year":"2025","journal-title":"Thromb Res"},{"issue":"3","key":"2026052610365531100_bib133","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/bjh.20242","article-title":"Prevalence and impact of additional CHIP mutations in JAK2V617F-positive ischaemic cerebrovascular patients","volume":"207","author":"Kristiansen","year":"2025","journal-title":"Br J Haematol"},{"issue":"1","key":"2026052610365531100_bib145","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.leukres.2008.06.002","article-title":"Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?","volume":"33","author":"Hasselbalch","year":"2009","journal-title":"Leuk Res"},{"issue":"8","key":"2026052610365531100_bib149","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1007\/s10787-025-01864-1","article-title":"The use of statins can reduce the risk of osteoarthritis and osteoporosis","volume":"33","author":"Zeng","year":"2025","journal-title":"Inflammopharmacology"},{"issue":"1","key":"2026052610365531100_bib150","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5152\/eurjrheum.2016.048","article-title":"An overview and management of osteoporosis","volume":"4","author":"S\u00f6zen","year":"2017","journal-title":"Eur J Rheumatol"},{"issue":"11","key":"2026052610365531100_bib151","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00198-004-1627-0","article-title":"An estimate of the worldwide prevalence, mortality and disability associated with hip fracture","volume":"15","author":"Johnell","year":"2004","journal-title":"Osteoporos Int"},{"issue":"6914","key":"2026052610365531100_bib152","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1136\/bmj.307.6914.1248","article-title":"Mortality and morbidity after hip fractures","volume":"307","author":"Keene","year":"1993","journal-title":"BMJ"},{"issue":"3","key":"2026052610365531100_bib153","doi-asserted-by":"crossref","first-page":"M101","DOI":"10.1093\/geronj\/45.3.M101","article-title":"Predictors of functional recovery one year following hospital discharge for hip fracture: a prospective study","volume":"45","author":"Magaziner","year":"1990","journal-title":"J Gerontol"},{"issue":"6","key":"2026052610365531100_bib154","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1007\/s00198-010-1419-7","article-title":"Medical costs of osteoporosis in the elderly Medicare population","volume":"22","author":"Blume","year":"2011","journal-title":"Osteoporos Int"},{"issue":"1","key":"2026052610365531100_bib155","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00198-020-05540-8","article-title":"Fragility fractures and health- related quality of life: does socio-economic status widen the gap? A population-based study","volume":"32","author":"Valentin","year":"2021","journal-title":"Osteoporos Int"},{"key":"2026052610365531100_bib156","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-4933-2-14","article-title":"Osteoporosis, inflammation and ageing","volume":"2","author":"Ginaldi","year":"2005","journal-title":"Immun Ageing"},{"issue":"4","key":"2026052610365531100_bib157","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s11914-009-0023-2","article-title":"Proinflammatory cytokines and osteoporosis","volume":"7","author":"McLean","year":"2009","journal-title":"Curr Osteoporos Rep"},{"issue":"1","key":"2026052610365531100_bib158","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1556\/EuJMI-D-14-00035","article-title":"Ageing and the immune system: focus on macrophages","volume":"5","author":"Linehan","year":"2015","journal-title":"Eur J Microbiol Immunol (Bp)"},{"issue":"3","key":"2026052610365531100_bib159","doi-asserted-by":"crossref","first-page":"101791","DOI":"10.1016\/j.berh.2022.101791","article-title":"Where is bone science taking us?","volume":"36","author":"Langdahl","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"2026052610365531100_bib167","first-page":"182","article-title":"Alendronate promotes osteoblast differentiation and bone formation in ovariectomy-induced osteoporosis through interferon-\u03b2\/signal transducer and activator of transcription 1 pathway","volume":"15","author":"Ma","year":"2018","journal-title":"Exp Ther Med"},{"issue":"9","key":"2026052610365531100_bib168","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/nm.2007","article-title":"Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis","volume":"15","author":"Zhao","year":"2009","journal-title":"Nat Med"},{"key":"2026052610365531100_bib169","doi-asserted-by":"crossref","first-page":"116140","DOI":"10.1016\/j.bone.2021.116140","article-title":"Cardiotrophin like cytokine factor 1 (CLCF1) alleviates bone loss in osteoporosis mouse models by suppressing osteoclast differentiation through activating interferon signaling and repressing the nuclear factor-\u03baB signaling pathway","volume":"153","author":"Yokota","year":"2021","journal-title":"Bone"},{"key":"2026052610365531100_bib170","doi-asserted-by":"crossref","first-page":"1095577","DOI":"10.3389\/fimmu.2022.1095577","article-title":"Targeting STING: from antiviral immunity to treat osteoporosis","volume":"13","author":"Gao","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"2026052610365531100_bib171","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrendo.2012.36","article-title":"Arterial calcification and bone physiology: role of the bone- vascular axis","volume":"8","author":"Thompson","year":"2012","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"2026052610365531100_bib172","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1080\/13697137.2016.1200550","article-title":"Associations between osteoporosis and coronary artery disease in postmenopausal women","volume":"19","author":"Lee","year":"2016","journal-title":"Climacteric"},{"issue":"1","key":"2026052610365531100_bib173","doi-asserted-by":"crossref","first-page":"27827","DOI":"10.1038\/s41598-024-78707-6","article-title":"Elucidating common biomarkers and pathways of osteoporosis and aortic valve calcification: insights into new therapeutic targets","volume":"14","author":"Lan","year":"2024","journal-title":"Sci Rep"},{"issue":"2","key":"2026052610365531100_bib174","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/bjh.18845","article-title":"Interferon alpha-2 treatment reduces circulating neutrophil extracellular trap levels in myeloproliferative neoplasms","volume":"202","author":"Massarenti","year":"2023","journal-title":"Br J Haematol"},{"key":"2026052610365531100_bib175","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.rinim.2014.03.001","article-title":"Evidence for simvastatin anti- inflammatory actions based on quantitative analyses of NETosis and other inflammation\/oxidation markers","volume":"4","author":"Al-Ghoul","year":"2014","journal-title":"Results Immunol"},{"key":"2026052610365531100_bib176","doi-asserted-by":"crossref","first-page":"1493684","DOI":"10.1155\/2023\/1493684","article-title":"Simvastatin reduces NETosis to attenuate severe asthma by inhibiting PAD4 expression","volume":"2023","author":"Chen","year":"2023","journal-title":"Oxid Med Cell Longev"},{"issue":"8","key":"2026052610365531100_bib177","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1038\/s41375-023-01967-0","article-title":"Clinical features and genomic landscape of myeloproliferative neoplasm (MPN) patients with autoimmune and inflammatory diseases (AID)","volume":"37","author":"Elessa","year":"2023","journal-title":"Leukemia"},{"key":"2026052610365531100_bib178","doi-asserted-by":"crossref","first-page":"1208089","DOI":"10.3389\/fonc.2023.1208089","article-title":"Myeloproliferative neoplasms - blurring the lines between cancer and chronic inflammatory disorder","volume":"13","author":"Soyfer","year":"2023","journal-title":"Front Oncol"},{"issue":"10","key":"2026052610365531100_bib181","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.3109\/10428194.2013.764417","article-title":"Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis","volume":"54","author":"Skov","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2026052610365531100_bib182","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1080\/10428194.2016.1262032","article-title":"The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms","volume":"58","author":"Skov","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2026052610365531100_bib183","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.atherosclerosis.2004.02.016","article-title":"Statin-induced immunomodulatory effects on human T cells in vivo","volume":"175","author":"Fehr","year":"2004","journal-title":"Atherosclerosis"},{"key":"2026052610365531100_bib184","doi-asserted-by":"crossref","first-page":"866610","DOI":"10.3389\/fimmu.2022.866610","article-title":"Patients with myeloproliferative neoplasms harbor high frequencies of CD8 T cell- platelet aggregates associated with T cell suppression","volume":"13","author":"Carnaz Sim\u00f5es","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"2026052610365531100_bib185","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41568-025-00888-7","article-title":"Neutrophil extracellular traps in cancer","volume":"26","author":"Shahzad","year":"2026","journal-title":"Nat Rev Cancer"},{"issue":"suppl 1","key":"2026052610365531100_bib186","doi-asserted-by":"crossref","first-page":"ehae666.3293","DOI":"10.1093\/eurheartj\/ehae666.3293","article-title":"The high-dose statin treatment reduces neutrophil extracellular traps formation in patients with coronary artery disease","volume":"45","author":"Stepien","year":"2024","journal-title":"Eur Heart J"},{"issue":"5","key":"2026052610365531100_bib187","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.5114\/aoms\/158546","article-title":"The effects of statins on the function and differentiation of blood cells","volume":"19","author":"Chamani","year":"2023","journal-title":"Arch Med Sci"},{"issue":"19","key":"2026052610365531100_bib188","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.3390\/cancers15194787","article-title":"Unraveling the anticancer potential of statins: mechanisms and clinical significance","volume":"15","author":"Zaky","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"50","key":"2026052610365531100_bib189","doi-asserted-by":"crossref","first-page":"82482","DOI":"10.18632\/oncotarget.12694","article-title":"Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models","volume":"7","author":"Wolfe","year":"2016","journal-title":"Oncotarget"},{"key":"2026052610365531100_bib190","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.canlet.2020.05.005","article-title":"Attenuation of the pro-inflammatory signature of lung cancer derived mesenchymal stromal cells by statins","volume":"484","author":"Galland","year":"2020","journal-title":"Cancer Lett"},{"issue":"1","key":"2026052610365531100_bib191","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13046-021-02041-2","article-title":"Statins: a repurposed drug to fight cancer","volume":"40","author":"Jiang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"2026052610365531100_bib192","doi-asserted-by":"crossref","first-page":"115644","DOI":"10.1016\/j.bcp.2023.115644","article-title":"Anti- fibrotic effects of statin drugs: a review of evidence and mechanisms","volume":"214","author":"Dolivo","year":"2023","journal-title":"Biochem Pharmacol"},{"issue":"11","key":"2026052610365531100_bib193","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.3390\/pharmaceutics17111425","article-title":"Matrix metalloproteinase-9 (MMP-9) as a therapeutic target: insights into molecular pathways and clinical applications","volume":"17","author":"Wolosowicz","year":"2025","journal-title":"Pharmaceutics"},{"issue":"1","key":"2026052610365531100_bib194","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cmet.2019.04.002","article-title":"Cholesterol induces CD8+ T cell exhaustion in the tumor microenvironment","volume":"30","author":"Ma","year":"2019","journal-title":"Cell Metab"},{"key":"2026052610365531100_bib195","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.3389\/fimmu.2020.02093","article-title":"Remodeling the bone marrow microenvironment - a proposal for targeting pro-inflammatory contributors in MPN","volume":"11","author":"Jutzi","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"2026052610365531100_bib196","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/jid.2014.529","article-title":"Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo","volume":"135","author":"Agarwal","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"10","key":"2026052610365531100_bib197","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1038\/s41375-025-02706-3","article-title":"Association of the composition of the bone marrow tumor microenvironment in BCR::ABL1-negative myeloproliferative neoplasms with IFN-\u03b3 signaling and driver mutations","volume":"39","author":"Bauer","year":"2025","journal-title":"Leukemia"},{"issue":"12","key":"2026052610365531100_bib198","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood-2016-10-696005","article-title":"Myeloproliferative neoplasm stem cells","volume":"129","author":"Mead","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2026052610365531100_bib199","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm1388","article-title":"Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells","volume":"12","author":"Ito","year":"2006","journal-title":"Nat Med"},{"issue":"11","key":"2026052610365531100_bib200","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1089\/ars.2008.2114","article-title":"Regulation of reactive oxygen species and genomic stability in hematopoietic stem cells","volume":"10","author":"Naka","year":"2008","journal-title":"Antioxid Redox Signal"},{"issue":"11","key":"2026052610365531100_bib201","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1182\/blood-2011-01-330050","article-title":"Accumulation of oxidative DNA damage restricts the self-renewal capacity of human hematopoietic stem cells","volume":"118","author":"Yahata","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2026052610365531100_bib202","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1182\/blood-2011-07-367755","article-title":"HSCs: stressing out over ROS","volume":"118","author":"Pang","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2026052610365531100_bib203","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.exphem.2016.06.253","article-title":"Aging of hematopoietic stem cells: DNA damage and mutations?","volume":"44","author":"Moehrle","year":"2016","journal-title":"Exp Hematol"},{"issue":"19","key":"2026052610365531100_bib204","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1182\/blood-2009-08-240580","article-title":"Hypercholesterolemia promotes bone marrow cell mobilization by perturbing the SDF-1:CXCR4 axis","volume":"115","author":"Gomes","year":"2010","journal-title":"Blood"},{"issue":"19","key":"2026052610365531100_bib205","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1182\/blood-2010-02-261388","article-title":"Cholesterol activates vascular niche and hematopoiesis","volume":"115","author":"Rafii","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2026052610365531100_bib208","doi-asserted-by":"crossref","first-page":"e000241","DOI":"10.1161\/JAHA.113.000241","article-title":"Hypercholesterolemia induces oxidant stress that accelerates the ageing of hematopoietic stem cells","volume":"3","author":"Tie","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"2026052610365531100_bib209","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/stem.1939","article-title":"Hematopoietic stem\/progenitor cells directly contribute to arteriosclerotic progression via integrin \u03b22","volume":"33","author":"Wang","year":"2015","journal-title":"Stem Cells"},{"issue":"11","key":"2026052610365531100_bib206","doi-asserted-by":"crossref","first-page":"e47286","DOI":"10.1371\/journal.pone.0047286","article-title":"Hematopoietic stem\/progenitor cell proliferation and differentiation is differentially regulated by high- density and low-density lipoproteins in mice","volume":"7","author":"Feng","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"2026052610365531100_bib207","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.atherosclerosis.2013.03.031","article-title":"Hypercholesterolemia and reduced HDL-C promote hematopoietic stem cell proliferation and monocytosis: studies in mice and FH children","volume":"229","author":"Tolani","year":"2013","journal-title":"Atherosclerosis"},{"issue":"6","key":"2026052610365531100_bib211","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.3390\/nu11061394","article-title":"Modulation of bone and marrow niche by cholesterol","volume":"11","author":"Yin","year":"2019","journal-title":"Nutrients"},{"issue":"10","key":"2026052610365531100_bib212","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/j.immuni.2025.09.012","article-title":"Inflammation in atherosclerosis: lessons and therapeutic implications","volume":"58","author":"Libby","year":"2025","journal-title":"Immunity"},{"key":"2026052610365531100_bib213","doi-asserted-by":"publisher","DOI":"10.1101\/2025.09.15.676283","article-title":"Hypercholesterolaemia promotes epigenetic memory in hematopoietic stem cells that persists after lipid lowering and causes systemic immunometabolic dysfunction mediated by macrophage metabolic reprogramming","author":"Purvis","year":"18  2025","journal-title":"bioRxiv"},{"issue":"7","key":"2026052610365531100_bib210","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.3390\/ijms17071162","article-title":"Hypercholesterolemia tunes hematopoietic stem\/progenitor cells for inflammation and atherosclerosis","volume":"17","author":"Ma","year":"2016","journal-title":"Int J Mol Sci"},{"key":"2026052610365531100_bib214","doi-asserted-by":"crossref","first-page":"100295","DOI":"10.1016\/j.eclinm.2020.100295","article-title":"Two-fold risk of pneumonia and respiratory mortality in individuals with myeloproliferative neoplasm: a population-based cohort study","volume":"21","author":"Pedersen","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"9","key":"2026052610365531100_bib222","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.3324\/haematol.2019.235648","article-title":"Ruxolitinib and interferon-\u03b12 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study","volume":"105","author":"S\u00f8rensen","year":"2020","journal-title":"Haematologica"},{"issue":"20","key":"2026052610365531100_bib223","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1182\/bloodadvances.2024013170","article-title":"Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera","volume":"8","author":"S\u00f8rensen","year":"2024","journal-title":"Blood Adv"},{"issue":"12","key":"2026052610365531100_bib224","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.21873\/anticanres.15410","article-title":"Repurposing metformin for cancer treatment: a great challenge of a promising drug","volume":"41","author":"Saengboonmee","year":"2021","journal-title":"Anticancer Res"},{"key":"2026052610365531100_bib225","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.288404","article-title":"Metformin alleviates side effects and supports the resumption of interferon therapy in polycythemia vera and essential thrombocythemia","author":"Reeves","year":"27  2025","journal-title":"Haematologica"},{"issue":"1","key":"2026052610365531100_bib226","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11095-024-03811-1","article-title":"Repurposing of metabolic drugs metformin and simvastatin as an emerging class of cancer therapeutics","volume":"42","author":"Maurya","year":"2025","journal-title":"Pharm Res"},{"issue":"13","key":"2026052610365531100_bib229","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1182\/bloodadvances.2024012880","article-title":"Treatment approach and outcomes of patients with accelerated\/blast-phase myeloproliferative neoplasms in the current era","volume":"8","author":"Patel","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"2026052610365531100_bib230","doi-asserted-by":"crossref","first-page":"828","DOI":"10.3324\/haematol.2023.283950","article-title":"Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia","volume":"110","author":"Patel","year":"2025","journal-title":"Haematologica"},{"issue":"5","key":"2026052610365531100_bib231","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1182\/bloodadvances.2025018724","article-title":"Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms","volume":"10","author":"Leiva","year":"2026","journal-title":"Blood Adv"},{"issue":"20","key":"2026052610365531100_bib232","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1182\/blood.2024027125","article-title":"HiJAKing the hematopoietic system: a low-frequency JAK2V617F clone drives myeloproliferative neoplasm pathology","volume":"146","author":"Bonal","year":"2025","journal-title":"Blood"},{"issue":"20","key":"2026052610365531100_bib233","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1182\/blood.2025030551","article-title":"Hijack the HiJAKer: rethinking therapy for JAK2-mutant MPN","volume":"146","author":"Zenke","year":"2025","journal-title":"Blood"},{"key":"2026052610365531100_bib234","doi-asserted-by":"publisher","DOI":"10.1101\/2025.04.15.2532566","article-title":"Analysis of the effects of statin therapy on clonal dynamics in clonal haematopoiesis of indeterminate potential: insights from the English Longitudinal Study of Ageing","author":"Musson","year":"19  2025","journal-title":"medRxiv"},{"key":"2026052610365531100_bib235","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2026.300445","article-title":"Metformin. Interferon\u2019s dancing partner","author":"Hasselbalch","year":"19  2026","journal-title":"Haematologica"},{"key":"2026052610365531100_bib236","doi-asserted-by":"crossref","first-page":"1459154","DOI":"10.3389\/frhem.2024.1459154","article-title":"The CHIP-clinic as the catalyst of preventive medicine","volume":"3","author":"Hasselbalch","year":"2024","journal-title":"Front Hematol"},{"issue":"suppl 1","key":"2026052610365531100_bib237","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood-2025-446","article-title":"Statin use and the risk of acute myeloid leukemia: a retrospective propensity-matched cohort study","volume":"146","author":"Al-Nusair","year":"2025","journal-title":"Blood"},{"issue":"15","key":"2026052610365531100_bib238","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1182\/bloodadvances.2023009818","article-title":"Statin use in myelodysplastic syndromes is associated with a better survival and decreased progression to leukemia","volume":"7","author":"Afzal","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"2026052610365531100_bib239","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1182\/blood.V93.4.1308","article-title":"Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach","volume":"93","author":"Dimitroulakos","year":"1999","journal-title":"Blood"},{"issue":"5-6","key":"2026052610365531100_bib240","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3109\/10428190109097663","article-title":"Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia","volume":"40","author":"Minden","year":"2001","journal-title":"Leuk Lymphoma"},{"issue":"suppl 1","key":"2026052610365531100_bib241","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1182\/blood-2024-198761","article-title":"Statins kill acute myeloid leukemia cells through low-density lipoprotein receptor-mediated unfolded protein response activation","volume":"144","author":"Yasuda","year":"2024","journal-title":"Blood"},{"issue":"12","key":"2026052610365531100_bib242","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1002\/2211-5463.70104","article-title":"Statins induce monocytic differentiation in acute myeloid leukemia cells through the KLF4\/DPYSL2A axis","volume":"15","author":"Noura","year":"2025","journal-title":"FEBS Open Bio"},{"issue":"5","key":"2026052610365531100_bib243","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.3324\/haematol.2022.282019","article-title":"Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blast phase myeloproliferative neoplasm","volume":"108","author":"Gangat","year":"2023","journal-title":"Haematologica"},{"issue":"2","key":"2026052610365531100_bib244","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/bjh.18853","article-title":"Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms","volume":"202","author":"Systchenko","year":"2023","journal-title":"Br J Haematol"},{"issue":"9","key":"2026052610365531100_bib245","doi-asserted-by":"crossref","first-page":"e70202","DOI":"10.1002\/hem3.70202","article-title":"Outcome of patients with accelerated and blast-phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination-a FIM study","volume":"9","author":"Orvain","year":"2025","journal-title":"Hemasphere"},{"issue":"445","key":"2026052610365531100_bib246","doi-asserted-by":"crossref","first-page":"eaaq1240","DOI":"10.1126\/scitranslmed.aaq1240","article-title":"Statins enhance efficacy of venetoclax in blood cancers","volume":"10","author":"Lee","year":"2018","journal-title":"Sci Transl Med"},{"issue":"21","key":"2026052610365531100_bib247","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1182\/blood.V118.21.2816.2816","article-title":"A mechanistic rationale for the use of statins to enhance JAK inhibitor therapy in MPNs","volume":"118","author":"Griner","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2026052610365531100_bib248","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/bjh.19107","article-title":"Ratio of stemness to interferon signalling as a biomarker and therapeutic target of MPN progression to AML","volume":"204","author":"de Castro","year":"2024","journal-title":"Br J Haematol"},{"issue":"5","key":"2026052610365531100_bib249","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/leu.2010.324","article-title":"Interferon-\u03b1 in acute myeloid leukemia: an old drug revisited Leukemia","volume":"25","author":"Anguille","year":"2011","journal-title":"Leukemia"},{"issue":"1","key":"2026052610365531100_bib250","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/bjh.19173","article-title":"Proof of concept of triple COMBI therapy to prohibit MPN progression to AML","volume":"204","author":"Hasselbalch","year":"2024","journal-title":"Br J Haematol"},{"issue":"7","key":"2026052610365531100_bib251","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1182\/blood-2006-08-044446","article-title":"Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study","volume":"109","author":"Kornblau","year":"2007","journal-title":"Blood"},{"key":"2026052610365531100_bib252","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/bjh.13035","article-title":"SWOG0919: a phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia","volume":"167","author":"Advani","year":"2014","journal-title":"Br J Haematol"},{"key":"2026052610365531100_bib253","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.leukres.2018.01.021","article-title":"Report of the relapsed\/ refractory cohort of SWOG S0919: a phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML)","volume":"67","author":"Advani","year":"2018","journal-title":"Leuk Res"},{"issue":"9","key":"2026052610365531100_bib254","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/s41375-025-02668-6","article-title":"Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct geranylgeranyl pyrophosphate, for induction of an adaptive stress response","volume":"39","author":"Skuli","year":"2025","journal-title":"Leukemia"},{"issue":"9","key":"2026052610365531100_bib255","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/sj.leu.2402196","article-title":"Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells","volume":"15","author":"Xia","year":"2001","journal-title":"Leukemia"},{"issue":"17","key":"2026052610365531100_bib256","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.1158\/0008-5472.CAN-14-0130","article-title":"Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop","volume":"74","author":"Pandyra","year":"2014","journal-title":"Cancer Res"},{"key":"2026052610365531100_bib257","doi-asserted-by":"crossref","first-page":"111378","DOI":"10.1016\/j.biopha.2021.111378","article-title":"HMGCS1 drives drug-resistance in acute myeloid leukemia through endoplasmic reticulum-UPR-mitochondria axis","volume":"137","author":"Zhou","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"2026052610365531100_bib258","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s44321-024-00024-2","article-title":"Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells","volume":"16","author":"Mueller","year":"2024","journal-title":"EMBO Mol Med"},{"key":"2026052610365531100_bib259","doi-asserted-by":"crossref","first-page":"115644","DOI":"10.1016\/j.bcp.2023.115644","article-title":"Anti- fibrotic effects of statin drugs: a review of evidence and mechanisms","volume":"214","author":"Dolivo","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"2026052610365531100_bib260","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s10741-024-10418-6","article-title":"Interplay of the heart, spleen, and bone marrow in heart failure: the role of spenic extramedullary hematopoiesis","volume":"29","author":"Hiraiwa","year":"2024","journal-title":"Heart Fail Rev"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3587\/2519684\/blooda_adv-2026-019625-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3587\/2519684\/blooda_adv-2026-019625-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:37:34Z","timestamp":1779806254000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/10\/3587\/566871\/Prime-time-for-the-use-of-statins-in-MPNs-from"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":260,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,5,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026019625","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,26]]},"published":{"date-parts":[[2026,5,15]]}}}